Search Results

There are 7552 results for: content related to: Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis

  1. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients


    Volume 12, Issue 10, December 2010, Pages: 657–663, Sameh Adel Fayek, Wana Mantipisitkul, Flavia Rasetto, Raghava Munivenkatappa, Rolf N. Barth and Benjamin Philosophe

    Version of Record online : 17 NOV 2010, DOI: 10.1111/j.1477-2574.2010.00226.x

  2. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients

    Transplant Infectious Disease

    Volume 11, Issue 2, April 2009, Pages: 106–111, R.L. Brady, K. Green, C. Frei and P. Maxwell

    Version of Record online : 27 NOV 2008, DOI: 10.1111/j.1399-3062.2008.00356.x

  3. You have free access to this content
    Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

    Liver Transplantation

    Volume 12, Issue 1, January 2006, Pages: 112–116, Jeong M. Park, Kathleen D. Lake, Juan D. Arenas and Robert J. Fontana

    Version of Record online : 28 DEC 2005, DOI: 10.1002/lt.20562

  4. You have free access to this content
    IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis

    American Journal of Transplantation

    Volume 11, Issue 1, January 2011, Pages: 18–21, A. C. Kalil, J. Sun and D. F. Florescu

    Version of Record online : 29 NOV 2010, DOI: 10.1111/j.1600-6143.2010.03342.x

  5. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease

    Transplant Infectious Disease

    Volume 6, Issue 3, September 2004, Pages: 101–109, D.J. Taber, E. Ashcraft, G.M. Baillie, S. Berkman, J. Rogers, P.K. Baliga, P.R. Rajagopalan, A. Lin, O. Emovon, F. Afzal and K.D. Chavin

    Version of Record online : 29 NOV 2004, DOI: 10.1111/j.1399-3062.2004.00066.x

  6. Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients

    Pediatric Transplantation

    Volume 16, Issue 3, May 2012, Pages: 294–301, D. F. Florescu, A. N. Langnas, W. Grant, D. F. Mercer, J. Botha, F. Qiu, L. Shafer and A. C. Kalil

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1399-3046.2011.01628.x

  7. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients

    Transplant Infectious Disease

    Volume 18, Issue 6, December 2016, Pages: 904–912, Seth Heldenbrand, Chenghui Li, Rosemary P. Cross, Kelly A. DePiero, Travis B. Dick, Kara Ferguson, Miae Kim, Erin Newkirk, Jeong M. Park, Janice Sudaria-Kerr, Eric M. Tichy, Kimi R. Ueda, Renee Weng, Jesse Wisniewski and Steven Gabardi

    Version of Record online : 7 NOV 2016, DOI: 10.1111/tid.12609

  8. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration

    Transplant Infectious Disease

    Volume 17, Issue 6, December 2015, Pages: 810–815, M. Takahata, S. Hashino, M. Nishio, J. Sugita, A. Shigematsu, M. Onozawa, K. Fujimoto, T. Endo, T. Kondo, J. Tanaka, M. Imamura and T. Teshima

    Version of Record online : 5 NOV 2015, DOI: 10.1111/tid.12456

  9. You have free access to this content
    Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

    Intervention Review

    The Cochrane Library

    Elisabeth M Hodson, Maleeka Ladhani, Angela C Webster, Giovanni FM Strippoli and Jonathan C Craig

    Published Online : 28 FEB 2013, DOI: 10.1002/14651858.CD003774.pub4

  10. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure

    Transplant Infectious Disease

    Volume 12, Issue 3, June 2010, Pages: 213–219, S. Lefeuvre, P. Chevalier, C. Charpentier, R. Zekkour, L. Havard, M. Benammar, C. Amrein, V. Boussaud, A. Lillo-Le Louët, R. Guillemain and E.M. Billaud

    Version of Record online : 20 JAN 2010, DOI: 10.1111/j.1399-3062.2010.00491.x

  11. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis

    Transplant Infectious Disease

    Volume 15, Issue 2, April 2013, Pages: 163–170, S.P. Hammond, S.T. Martin, K. Roberts, S. Gabardi, A.L. Fuhlbrigge, P.C. Camp, H.J. Goldberg, F.M. Marty and L.R. Baden

    Version of Record online : 12 DEC 2012, DOI: 10.1111/tid.12036

  12. You have free access to this content
    Impact of Cytomegalovirus Disease in D+/R– Kidney Transplant Patients Receiving 6 Months Low-Dose Valganciclovir Prophylaxis

    American Journal of Transplantation

    Volume 11, Issue 9, September 2011, Pages: 1936–1942, F. L. Luan, M. Kommareddi and A. O. Ojo

    Version of Record online : 9 AUG 2011, DOI: 10.1111/j.1600-6143.2011.03611.x

  13. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective

    Transplant Infectious Disease

    Volume 17, Issue 3, June 2015, Pages: 334–341, M. Kacer, L. Kielberger, M. Bouda and T. Reischig

    Version of Record online : 26 MAY 2015, DOI: 10.1111/tid.12383

  14. Fabrication and characterization of poly(butylene succinate)-grafted carbon fiber/poly(L-lactide) nanocomposites

    Journal of Polymer Science Part A: Polymer Chemistry

    Volume 46, Issue 13, 1 July 2008, Pages: 4433–4441, Sungil Moon and Masatoshi Iji

    Version of Record online : 27 MAY 2008, DOI: 10.1002/pola.22775

  15. Cytomegalovirus prophylaxis with valganciclovir in African–American renal allograft recipients based on donor/recipient serostatus

    Clinical Transplantation

    Volume 19, Issue 2, April 2005, Pages: 273–278, Scott A Gruber, James Garnick, Katherina Morawski, Dale H Sillix, Miguel S West, Darla K Granger, Jose M El-Amm, George J Alangaden, Pranatharthi Chandrasekar and Abdolreza Haririan

    Version of Record online : 14 FEB 2005, DOI: 10.1111/j.1399-0012.2005.00337.x

  16. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation

    Clinical Transplantation

    Volume 21, Issue 1, January/February 2007, Pages: 80–85, Kai Lopau, Alexandra Greser and Christoph Wanner

    Version of Record online : 30 NOV 2006, DOI: 10.1111/j.1399-0012.2006.00586.x

  17. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis

    Transplant Infectious Disease

    Volume 17, Issue 2, April 2015, Pages: 163–173, D.R. Stevens, D. Sawinski, E. Blumberg, N. Galanakis, R.D. Bloom and J. Trofe-Clark

    Version of Record online : 6 FEB 2015, DOI: 10.1111/tid.12349

  18. You have free access to this content
    Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation

    Transplant Infectious Disease

    Volume 9, Issue 2, June 2007, Pages: 102–107, A. Busca, P. De Fabritiis, V. Ghisetti, T. Allice, M. Mirabile, G. Gentile, F. Locatelli and M. Falda

    Version of Record online : 30 JAN 2007, DOI: 10.1111/j.1399-3062.2006.00183.x

  19. You have free access to this content
    Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice

    Transplant International

    Volume 28, Issue 9, September 2015, Pages: 1042–1054, Mario Fernández-Ruiz, Manuel Arias, Josep M. Campistol, David Navarro, Ernesto Gómez-Huertas, Gonzalo Gómez-Márquez, Juan Manuel Díaz, Domingo Hernández, Gabriel Bernal-Blanco, Frederic Cofan, Luisa Jimeno, Antonio Franco-Esteve, Esther González, Francesc J. Moreso, Carlos Gómez-Alamillo, Alicia Mendiluce, Enrique Luna-Huerta, José María Aguado and on behalf of the OPERA Study Group

    Version of Record online : 23 APR 2015, DOI: 10.1111/tri.12586

  20. You have free access to this content
    Loss of β2-laminin alters calcium sensitivity and voltage-gated calcium channel maturation of neurotransmission at the neuromuscular junction

    The Journal of Physiology

    Volume 593, Issue 1, 1 January 2015, Pages: 245–265, Kirat K. Chand, Kah Meng Lee, Mitja P. Schenning, Nickolas A. Lavidis and Peter G. Noakes

    Version of Record online : 1 DEC 2014, DOI: 10.1113/jphysiol.2014.284133